China Healthcare:Big is better for consistency evaluation

类别:行业研究 机构:国信证券(香港)金融控股有限公司 研究员:Jason Siu 日期:2018-01-12

Heart & brain drugs stunned 1st batch of consistency evaluation.

    On 29 Dec 2017, China’s FDA announced the first batch of 17 generic drug namesfor consistency evaluation on their quality and efficacy (仿制药质量和疗效一致性评价). Twelve of them were heart & brain medicines, among ten of which beinganti-hypertension drugs. The other five drugs were antibiotics, anti-psychotic drugs,anti-cancer and anti-viral for hepatitis and HIV. The latter anti-viral medicine fromChengdu Brilliant Pharma (成都倍特药业) was generic version of Tenofovir?(Disoproxil Fumarate) at 300mg, similar to Sinobiopharm’s (1177.HK, NR)Qingzhong.

    Sinobiopharm’s Tuotuo passed consistency evaluation.

    For HK-listed drug-maker, only one medicine was included into the list, namelySinobiopharm’s Tuotuo 托妥? (Rosuvastatin Calcium Tablets 瑞舒伐他汀钙片).

    This medicine, as a generic version of Crestor?, is well known to its cholesterollowering efficacy. Other heart and brain medicines on that list include genericversions of (1) Plavix? (Clopidogrel); (2) Monopril? (Fosinopril sodium); (3) Avapro?(Irbesartan HCl); (4) Zestril? or Prinivil? (Lisinopril); and (5) Cozaar? (Losartanpotassium). The generic version of Gefitinib Tablets (吉非替尼片) (anti-cancer)from a China A-share listed player had also been included into the list. It is worthnoting that, its tender price in 2017 stood at RMB1,680 per box (250mg) fromGuangxi Province, 29% discount to the original medicine (Iressa?) from AstraZeneca of RMB2,358 per box in Hubei and Sichuan Provinces.

    Consistency evaluation raises China drug-making standard.

    As cited by CFDA newsletter, consistent with government policy to provide qualitymedicine to Chinese masses, we see consistency evaluation will (1) improve themedicine production level from Chinese drug-makers, (2) guarantee drug safetyand effectiveness, (3) promote the sector’s technology upgrades; and (4) raisetheir global competitiveness. We expect more preferential selection of thoseChinese drug-makers whose medicines had passed the consistency evaluationduring central procurement from hospitals.

    Big is better for consistency evaluation.

    Note that, if there are more than three producers of the similar drug type (or drugstructure) getting qualified in consistency evaluation, those drug type or structurefailing to pass consistency evaluation shall not be selected in centralizedprocurement for hospitals. Moreover, we reckon that those medicines from biggerand reputed Chinese drug-makers would likely fulfill the consistency evaluationtests. Those HK-listed Chinese drug-makers with large capacities to produce qualitygeneric drugs include (1) Sinobiopharm; (2) CSPC (1093.HK, NR) and (3) FosunPharm (2196.HK, NR).



太阳纸业 持有 -- 研报
苏宁易购 中性 -- 研报
巨化股份 持有 -- 研报
永兴特钢 中性 -- 研报
家家悦 中性 -- 研报
永辉超市 中性 -- 研报
王府井 中性 -- 研报
重庆百货 中性 -- 研报
天虹股份 中性 -- 研报
步步高 中性 -- 研报
苏宁易购 中性 -- 研报


太阳纸业 0.70 0.36 研报
苏宁易购 0.70 0.56 研报
巨化股份 1.42 0.56 研报
永兴特钢 0 0 研报
永辉超市 0.62 0.64 研报
王府井 1.40 1.52 研报
家家悦 0 0 研报
天虹股份 0.86 0.76 研报
重庆百货 1.73 1.81 研报
步步高 0.88 1.22 研报


华鲁恒升 39 持有 持有
上汽集团 36 持有 买入
三一重工 33 持有 买入
中炬高新 32 持有 买入
中国国旅 32 持有 买入
万科A 31 买入 买入
保利地产 30 买入 买入
烽火通信 30 买入 持有
贵州茅台 30 持有 中性
当升科技 30 持有 买入
先导智能 30 持有 买入
中国巨石 28 持有 买入
扬农化工 28 持有 持有
恒瑞医药 27 持有 持有
中炬高新 27 持有 买入
伊利股份 27 持有 持有
长春高新 27 持有 持有


电子信息 624 91 288
生物制药 509 69 227
建筑建材 387 49 165
化工行业 365 53 134
机械行业 344 50 161
金融行业 330 29 123
商业百货 305 42 118
汽车制造 296 39 119
食品行业 283 30 99
房地产 263 26 133
酿酒行业 259 17 119
电子器件 258 47 129
农林牧渔 187 32 59
交通运输 184 30 99
服装鞋类 177 21 84
钢铁行业 170 28 25
酒店旅游 167 19 59